Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neurocutaneous Syndromes | 2 | 2022 | 6 | 0.800 |
Why?
|
| Brain Neoplasms | 7 | 2021 | 301 | 0.720 |
Why?
|
| Stress, Psychological | 4 | 2016 | 219 | 0.630 |
Why?
|
| Neoplasms | 6 | 2016 | 818 | 0.620 |
Why?
|
| Lipomatosis | 1 | 2018 | 2 | 0.610 |
Why?
|
| Eye Diseases | 1 | 2018 | 31 | 0.590 |
Why?
|
| Child, Preschool | 16 | 2021 | 1149 | 0.580 |
Why?
|
| Glioma | 4 | 2021 | 118 | 0.570 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 411 | 0.560 |
Why?
|
| Adaptation, Psychological | 2 | 2013 | 123 | 0.460 |
Why?
|
| Mothers | 2 | 2013 | 122 | 0.450 |
Why?
|
| Psychotherapy | 1 | 2012 | 16 | 0.390 |
Why?
|
| Child | 15 | 2022 | 2253 | 0.370 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2008 | 30 | 0.280 |
Why?
|
| Adolescent | 11 | 2021 | 3128 | 0.280 |
Why?
|
| Brain Stem Neoplasms | 2 | 2020 | 12 | 0.270 |
Why?
|
| Thrombosis | 1 | 2008 | 149 | 0.250 |
Why?
|
| Parents | 2 | 2016 | 127 | 0.230 |
Why?
|
| Humans | 23 | 2022 | 28167 | 0.230 |
Why?
|
| Medulloblastoma | 2 | 2016 | 18 | 0.220 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2015 | 10 | 0.220 |
Why?
|
| Camptothecin | 4 | 2016 | 16 | 0.210 |
Why?
|
| Histones | 2 | 2021 | 93 | 0.210 |
Why?
|
| Parent-Child Relations | 2 | 2016 | 73 | 0.200 |
Why?
|
| Male | 13 | 2021 | 13510 | 0.200 |
Why?
|
| Female | 16 | 2021 | 15191 | 0.200 |
Why?
|
| Tuberous Sclerosis | 1 | 2022 | 3 | 0.190 |
Why?
|
| Neurofibromatosis 1 | 1 | 2022 | 6 | 0.190 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2022 | 10 | 0.190 |
Why?
|
| Oncolytic Virotherapy | 1 | 2021 | 12 | 0.180 |
Why?
|
| Young Adult | 6 | 2020 | 2738 | 0.180 |
Why?
|
| Treatment Outcome | 3 | 2018 | 2383 | 0.170 |
Why?
|
| Mercaptopurine | 1 | 2020 | 1 | 0.170 |
Why?
|
| Directly Observed Therapy | 1 | 2020 | 1 | 0.170 |
Why?
|
| Text Messaging | 1 | 2020 | 22 | 0.170 |
Why?
|
| Supratentorial Neoplasms | 1 | 2020 | 4 | 0.170 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 41 | 0.160 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 44 | 0.160 |
Why?
|
| Medication Adherence | 1 | 2020 | 48 | 0.160 |
Why?
|
| Quality of Life | 2 | 2016 | 492 | 0.160 |
Why?
|
| Infant | 5 | 2018 | 1014 | 0.160 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 10 | 0.150 |
Why?
|
| Pyrimidinones | 1 | 2018 | 16 | 0.150 |
Why?
|
| N-Terminal Acetyltransferase A | 1 | 2018 | 1 | 0.150 |
Why?
|
| N-Terminal Acetyltransferase E | 1 | 2018 | 1 | 0.150 |
Why?
|
| Astrocytoma | 1 | 2018 | 35 | 0.150 |
Why?
|
| Pyridones | 1 | 2018 | 35 | 0.150 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2018 | 12 | 0.150 |
Why?
|
| Developmental Disabilities | 1 | 2018 | 15 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2018 | 87 | 0.150 |
Why?
|
| Intellectual Disability | 1 | 2018 | 16 | 0.140 |
Why?
|
| Dacarbazine | 3 | 2016 | 15 | 0.140 |
Why?
|
| Disease Progression | 1 | 2018 | 474 | 0.130 |
Why?
|
| Adult | 7 | 2022 | 7765 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 826 | 0.130 |
Why?
|
| Phenotype | 1 | 2018 | 679 | 0.120 |
Why?
|
| Cerebellar Neoplasms | 1 | 2016 | 28 | 0.120 |
Why?
|
| Hematoma, Subdural, Chronic | 1 | 2015 | 7 | 0.120 |
Why?
|
| Uncertainty | 1 | 2015 | 25 | 0.120 |
Why?
|
| Benzenesulfonates | 1 | 2015 | 18 | 0.120 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 29 | 0.120 |
Why?
|
| Imines | 1 | 2015 | 21 | 0.120 |
Why?
|
| Sarcoma | 1 | 2015 | 29 | 0.120 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 15 | 0.110 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 70 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2015 | 105 | 0.110 |
Why?
|
| Child Behavior Disorders | 1 | 2013 | 25 | 0.100 |
Why?
|
| Pons | 1 | 2012 | 7 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2012 | 7 | 0.100 |
Why?
|
| Retinoblastoma | 1 | 2012 | 8 | 0.100 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 23 | 0.100 |
Why?
|
| Retinal Neoplasms | 1 | 2012 | 8 | 0.100 |
Why?
|
| Metalloporphyrins | 1 | 2012 | 18 | 0.100 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2012 | 32 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2012 | 34 | 0.100 |
Why?
|
| Hospitals, Pediatric | 1 | 2012 | 33 | 0.100 |
Why?
|
| Bevacizumab | 3 | 2020 | 103 | 0.090 |
Why?
|
| Mutation | 3 | 2021 | 849 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2012 | 194 | 0.090 |
Why?
|
| Middle Aged | 5 | 2015 | 7164 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2012 | 436 | 0.090 |
Why?
|
| Vincristine | 1 | 2010 | 9 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 32 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2010 | 32 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 678 | 0.080 |
Why?
|
| Prognosis | 2 | 2021 | 803 | 0.070 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2008 | 27 | 0.070 |
Why?
|
| Thrombophilia | 1 | 2008 | 10 | 0.070 |
Why?
|
| Diarrhea | 1 | 2008 | 56 | 0.070 |
Why?
|
| Hemostasis | 1 | 2008 | 48 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 55 | 0.070 |
Why?
|
| Survival Rate | 2 | 2020 | 430 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 302 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1015 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2015 | 75 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 224 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2022 | 2558 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2021 | 25 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 64 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 194 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 48 | 0.040 |
Why?
|
| Valproic Acid | 1 | 2020 | 15 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 91 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 283 | 0.040 |
Why?
|
| Enzyme Stability | 1 | 2018 | 31 | 0.040 |
Why?
|
| Syndrome | 1 | 2018 | 78 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2018 | 208 | 0.040 |
Why?
|
| Protein Binding | 1 | 2018 | 657 | 0.030 |
Why?
|
| Decorin | 1 | 2015 | 3 | 0.030 |
Why?
|
| Sulfatases | 1 | 2015 | 6 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2015 | 61 | 0.030 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2015 | 31 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 315 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 330 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 463 | 0.030 |
Why?
|
| Internal-External Control | 1 | 2013 | 17 | 0.030 |
Why?
|
| Lymphopenia | 1 | 2012 | 8 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 2012 | 10 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 98 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 101 | 0.020 |
Why?
|
| Karyotyping | 1 | 2012 | 25 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2012 | 32 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2013 | 89 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 238 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 806 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 323 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 144 | 0.020 |
Why?
|
| Medical Audit | 1 | 2010 | 15 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2010 | 47 | 0.020 |
Why?
|
| Hypertension | 1 | 2012 | 309 | 0.020 |
Why?
|
| Liver | 1 | 2012 | 441 | 0.020 |
Why?
|
| Health Status | 1 | 2010 | 148 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 1433 | 0.020 |
Why?
|
| Cephalosporins | 1 | 2008 | 18 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 969 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 4655 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 677 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 10416 | 0.010 |
Why?
|